Kura Kommentary
Progress By Collaboration: The Development of Kura’s Menin Inhibitor for AML Research
By Troy Wilson
In a recent video, From Lab to Clinic: The Origin and Journey of Menin Inhibitors for AML Research, Kura Oncology CEO Troy Wilson, Ph.D., J.D., details the history of Kura’s menin inhibitor with fellow pioneers in menin inhibitor research for acute myeloid leukemia (AML).
Following the debut of the video, Wilson penned a LinkedIn article accessible here. In this piece, he details history of Kura’s menin inhibitor and expresses gratitude for the academic researchers, advocacy partners and Kura leadership who were crucial in the research and development of our menin inhibitor program. Watch the full video here.
